Global Peripheral Nerve Stimulators (PNS) Medical Devices Pipeline Market Assessment Report 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peripheral Nerve Stimulators (PNS) – Medical Devices Pipeline Assessment, 2020” report has been added to ResearchAndMarkets.com’s offering.

“Peripheral Nerve Stimulators (PNS) – Medical Devices Pipeline Assessment, 2020” provides comprehensive information about the Peripheral Nerve Stimulators (PNS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

A PNS is a device, similar to the SCS, that is used to treat chronic pain disorders. A PNS is comprised of an electrical pacemaker that stimulates the peripheral nerve through the surgically-implanted electrodes.

Scope

• Extensive coverage of the Peripheral Nerve Stimulators (PNS) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Peripheral Nerve Stimulators (PNS) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of Peripheral Nerve Stimulators (PNS) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Peripheral Nerve Stimulators (PNS) Overview

3 Products under Development

3.1 Peripheral Nerve Stimulators (PNS) – Pipeline Products by Stage of Development

3.2 Peripheral Nerve Stimulators (PNS) – Pipeline Products by Territory

3.3 Peripheral Nerve Stimulators (PNS) – Pipeline Products by Regulatory Path

3.4 Peripheral Nerve Stimulators (PNS) – Pipeline Products by Estimated Approval Date

3.5 Peripheral Nerve Stimulators (PNS) – Ongoing Clinical Trials

4 Peripheral Nerve Stimulators (PNS) – Pipeline Products under Development by Companies

4.1 Peripheral Nerve Stimulators (PNS) Companies – Pipeline Products by Stage of Development

4.2 Peripheral Nerve Stimulators (PNS) – Pipeline Products by Stage of Development

5 Peripheral Nerve Stimulators (PNS) Companies and Product Overview

5.1 Actuated Medical Inc Company Overview

5.2 Cardionomic Inc (Inactive) Company Overview

5.3 Checkpoint Surgical Inc Company Overview

5.4 EMKinetics, Inc. Company Overview

5.5 Epineuron Technologies Inc Company Overview

5.6 Gondola Medical Technologies SA Company Overview

5.7 Noctrix Health Inc Company Overview

5.8 Remedee Labs SAS Company Overview

5.9 Washington University School of Medicine Company Overview

6 Peripheral Nerve Stimulators (PNS)- Recent Developments

6.1 Jan 21, 2020: Study of Sprint Peripheral Nerve Stimulation System demonstrates 12 months of low back pain relief following 60-day treatment

6.2 Dec 10, 2019: Study demonstrates 12-month relief of post-amputation pain following treatment with SPRINT PNS System

6.3 Dec 04, 2019: SPR Therapeutics announces 1000th Sprint PNS Procedure

6.4 Nov 13, 2019: Remedee Labs Breakthrough Endorphin Stimulation Solution Is Unveiled

6.5 Nov 13, 2019: New clinical trial into pain management started by leading French research hospital

6.6 Sep 23, 2019: Cala Health announces positive topline data from landmark PROSPECT study for essential tremor (ET)

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jqin9e

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900